The 5th World Congress of Cutaneous Lymphomas took place this year from April 11-13, 2024. This Congress brings together stakeholders across the oncology sphere, from basic scientists and hematologists to clinical oncologists and dermatopathologists, to discuss research advances and practical challenges in the field. One presentation from Professor Dr. Rudolf Stadler centered around the Phase 2 RESMAIN study. The study evaluated resminostat (Kinselby) as a potential maintenance treatment for people living with advanced cutaneous T-cell lymphoma (CTCL) such as Sézary syndrome or mycosis fungoides. A maintenance therapy is a treatment given to keep cancer from recurring after an initial therapy, such as chemotherapy.
According to a news release published on Pharmiweb, 201 individuals enrolled in the RESMAIN study. Participants with CTCL had achieved disease control. During the trial, they were given either reminostat or a placebo. Reminostat is an oral histone deacetylase inhibitor. It is designed to stop tumors from growing or spreading while strengthening the body’s immune response to cancer, a multipronged approach.
Findings from the study show that:
- Reminostat was generally well-tolerated. While some individuals did experience adverse reactions, these were mild-to-moderate and easily managed by participants.
- Participants receiving reminostat significantly reduced disease progression. The progression-free survival rate in those receiving reminostat was 97.6%, suggesting a high therapeutic efficacy. This progression-free survival rate was also sustained over time. Those taking reminostat did not experience disease progression for a median 24.3 months, which is 9.4 months longer than the participants who received the placebo.
- Reminostat also reduced the risk of developing new skin tumors or lesions and stopped existing tumors from growing or spreading.
Get the Facts: Cutaneous T-Cell Lymphoma (CTCL)
Cutaneous T-cell lymphoma is a type of non-Hodgkin’s lymphoma that primarily affects the skin. This cancer involves malignant T-cells, a type of white blood cell that plays a central role in the immune system. There are multiple subtypes of CTCL including lymphomatoid papulosis, Sézary syndrome, granulomatous slack skin, mycosis fungoides, and pagetoid reticulosis, also known as Woringer-Kolopp disease. Doctors don’t know the exact cause of CTCL, though some people think the cancer is the result of multiple environmental, genetic, and lifestyle factors.
CTCL causes various symptoms and skin manifestations as malignant T-cells localize to the skin. Signs and symptoms differ based on subtype but may include signs like widespread skin reddening or scaliness, alopecia, enlarged lymph nodes, extreme itchiness, nail malformations, an enlarged liver or spleen, abnormally rough skin on the palms or soles of the feet, and an outward turning of the eyelids in Sézary syndrome; or a red rash or patches of dry, red scaly skin on the trunk or buttocks, intensely itchy plaques on the skin with itchiness and pain, enlarged lymph nodes, and ulcerating tumors in mycosis fungoides.
Current treatment options for cutaneous T-cell lymphoma include photochemotherapy, Zolinza, topical chemotherapy, radiation therapy, retinoids, and chemotherapy. New treatment options are needed. While patients do have a spectrum of available therapies, these often do not prompt a complete response. Relapses are common, as are deletory health effects.
clinical trial CTCL cutaneous T-cell lymphoma Kinselby lymphoma oncology resminostat
Last modified: June 7, 2024
